|
|
Profile
|
Delegates :
Hong Seok Lim |
|
Incorporated :
August 27 , 1954 |
Paid in Capital :
80 Million yen |
Employees :
175 人 |
Address :
1-44-4, Tomigaya, Shibuya-ku, TOKYO
〒151-0063
|
TEL/FAX :
+81-3-6804-9643 / +81-3-3481-6061 |
URL：
http://jbpglobal.placenta.co.jp |
Attachment :
|
Mission/Background :
Management philosophy : Self Sufficiency & Self-Sustainability
Business Outline : Manufacturing and selling human placental injection “Laennec”, placental cosmetics, placental supplements and medical devices.
Research and Development of placenta and its extract. |
|
Technology & Business
|
Safety Scheme of JBP Placental Extract (Human) :
1) Donor Screening, negatives for virus & bacteria tests (HBV / HCV / HIV / treponema pallidum / gonorrhea / TB)
Screening by Donor’s overseas stay experience
Consent by Donor
2) Acceptance Inspection Testing
Individual inspection by weight, colour, smell, etc.
↓
NAT testing for HBV-DNA, HCV-RNA, HIV-1-RNA of all samples.
Virus testing methods are all validated accordingly.
3) Sterilization by 3 Different Methods
With organic solvent
With digestive enzyme+acid processing
With 121℃×20 minute autoclave (final sterilization)
All sterilization methods and processes are validated by spiking.
4) Product Specification Testing for Viruses
HBV / HCV / HIV / HTLV / Parvovirus-B19
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Laennec Injection
|
NDA filed
|
Approved in Japan, Korea, Russia, Azerbaijan, Georgia, and in Mongolia
|
Find a regional pharmaceutical companies/distributors who can support us in (1)registration and (2)sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Laennec has been approved in Japan, Russia, Mongolia, Korea, Azerbaijan and Georgia.
|
|
Alliance strategy
|
We are currently looking for a regional pharmaceutical companies/distributors who can support us in (1)registration and (2)sales and marketing of our biopharmaceutical “Laennec inj”,
targeting chronic hepatitis, cirrhosis, ALD and NAFLD.
|
|
|